THE SOLUTION Seeking a way to address these challenges, the manufacturer consulted Avient. In a relatively short time, the Avient team was able to formulate additives that performed well at lower LDRs. Finally, Avient’s willingness and ability to conduct and provide testing results saved the customer time and money.

AVIENT SOLUTION ADDRESSES CRITICAL MANUFACTURING PRODUCTIVITY ISSUES AND DELIVERS OVER $100,000 PER YEAR IN SAVINGS Avient helped the customer calculate costs for the 12-month period. With the Avient material, the manufacturer is expected to save $122,000 per year vs. silicone.

Copyright © 2022, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. Avient is committed to the needs of our healthcare customers.

Copyright © 2023, Avient Corporation. Avient makes no warranties or guarantees respecting suitability of either Avient’s products or the information for your process or end-use application. Avient is committed to the needs of our healthcare customers.

Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. Each of such adjustments has not yet occurred, are out of Avient’s control and/or cannot be reasonably predicted. For the same reasons, Avient is unable to address the probable significance of the unavailable information.

Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. For the same reasons, Avient is unable to address the probable significance of the unavailable information. Avient reflects 2023 adjusted EBITDA guidance of $500M and estimated run-rate CAPEX of $110M. 2023E (%) 27 78 89 84 82 80 77 88 81 76 70 69 60 54 (6) Av ie nt PP PM FM C C Avient Specialty Other Specialty / MULTIPLE EXPANSION Note: Avient reflects 2023 adjusted EBITDA guidance of $500M and closing share price of $31.18.

Patterson, Chairman, President and Chief Executive Officer, Avient Corporation. As such, we look forward to pursuing other acquisition opportunities and/or repurchasing Avient shares in the open market in the future.” About Avient Avient Corporation (NYSE: AVNT), with expected 2021 revenues of $4.75 billion, provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world.

Avient’s chief operating decision maker uses these financial measures to monitor and evaluate the ongoing performance of Avient and each business segment and to allocate resources. Avient reflects 2023 adjusted EBITDA guidance of $530M and estimated run-rate CAPEX of $110M. Avient Specialty Other Specialty / 2023E(%) 28 79 87 81 79 76 73 90 77 76 75 73 64 59 33 MULTIPLE EXPANSION Avient Specialty Other Specialty / Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89.

Animal Testing Policy AVIENT CORPORATION AND SUBSIDIARIES In the normal course of doing business, Avient is required to conduct testing to ensure the safety of its products. Reduce – Avient will only consider animal testing if it is a legal requirement, or to ensure the safety of our products, when no suitable alternatives are available. In these cases, Avient commits to minimize the number of animals as much as possible

Kronimus joined Avient in March 1999, and in addition to leading the company’s engineered materials business in Europe and India, also serves as Avient’s legal representative in the region, responsible for building and maintaining relationships with local governments and associations. In previous roles at Avient, Mr. Avient Corporation • 33587 Walker Road • Avon Lake, Ohio 44012 • 440.930.1000 • www.avient.com